BridgeBio Pharma price to sales ratio BBIO

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 18.8×
5-year median: 26.4×
Against its 5-year history: 18th; percentile: 0 is its lowest day, 100 its highest
5-year range: 12.5× to 138×
Peer median: 5.8×

BridgeBio Pharma's price to sales ratio is 18.8× as of Oct 23, 2026.

That is below its 5-year median of 26.4×, lower than on 82% of days in the last 5 years.

Over that time it ranged from 12.5× in Jan 2023 to 138× in Nov 2021.

The median for 10 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	18.8×	17.9×	42.6×
2025	41.3×	24.4×	70.6×
2024	24.3×	20.3×	26.3×
2023	71.0×	12.5×	71.0×
2022	12.8×	12.8×	37.9×
2021	43.1×	43.1×	138×

Against its peers

Companies in Drug Manufacturers - General nearest BridgeBio Pharma's size, closest first, today.

Company	Price to sales ratio
BBIOBridgeBio Pharma	18.8×
JAZZJazz Pharmaceuticals	3.0×
BMRNBiomarin Pharmaceutical	3.2×
CORTCorcept Therapeutics	11.2×
PTGXProtagonist Therapeutics	31.8×
TGTXTG Therapeutics	10.4×
ALKSAlkermes plc.	4.4×
AMRXAmneal Pharmaceuticals	2.1×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
BIIBBiogen	3.7×
Peer median	5.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on BridgeBio Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.